Pharvaris’s Oral HAE Prevention Data May Threaten BioCryst’s Orladeyo
The Swiss firm reported that its oral bradykinin B2 receptor antagonist reduced monthly hereditary angioedema attacks by 84.5% compared with placebo, suggesting biologic-like efficacy with an oral drug.
You may also be interested in...
The firm’s oral kallikrein inhibitor might offer a better overall profile for on-demand treatment than currently approved therapeutic and prophylactic agents, analysts said.
Public Company Edition: Arvinas grossed $350m in a private placement, while Xenon brought in $345m and Pharvaris raised $300m in follow-on public offerings. Fundraising remains challenging, however, so IGM Biosciences, Hansa Biopharma and other companies cut costs to save money.
Public Company Edition: Private Galderma raised $1bn but said its next likely financing will be an IPO. Also, Azitra went public while Turnstone, Apogee and Sagimet initiated the process; Sutro signed a royalty deal for up to $390m; and despite a follow-on offering mini-surge, cost cuts continue.